# Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

> **NCT07529951** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Eilean Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Polycythemia Vera (PV)
- Myelofibrosis (MF)

## Interventions

- **DRUG:** ZE74-0282

## Key facts

- **NCT ID:** NCT07529951
- **Lead sponsor:** Eilean Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07529951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07529951, "Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07529951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*